Compare Rockwell Automation (ROK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Recursion Pharmaceuticals Inc — how do they compare? Rockwell Automation trades at $466.2 (market cap $51.04B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Rockwell Automation is far larger — about 33.4× Recursion Pharmaceuticals Inc's market cap, and Rockwell Automation pays a 1.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ROK | RXRX | |
|---|---|---|
Market Cap | $51.04B | $1.53B |
Sector | Industrials | Health |
52-Week High | $495.08 | $6.79 |
52-Week Low | $328.67 | $2.84 |
Enterprise Value | $54.67B | $946.50M |
Dividend Yield | 1.2% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
